MSD has successfully tested a new pneumococcal vaccine

MSD has published the results of clinical trials of a 15-valent vaccine against pneumococcus. The data obtained are so convincing that the company is preparing to submit registration applications to regulatory authorities around the world, says FiercePharma.

At the same time was presented the data of the two studies: among persons over the age of 18 living with HIV, and patients older than 50 years who also received injections of the vaccine it protects against the flu. In both studies, candidate vaccine V114 contributed to the development of immune response against all 15 serotypes of pneumococcus.

Development MSD competes with experimental pneumococcal vaccine Pfizer intended for prevention of infection of 20 serotypes of streptococcus pneumoniae. Pfizer presented the results of a clinical phase III studies in March and also preparing for the filing of the registration statement.

Leave a Reply

Your email address will not be published. Required fields are marked *


For the six months Kurgan “Synthesis” increased revenue by 42%

Revenue of JSC “Sintez” (part of the Allium Group) for 6 months of 2020 has increased by 42% year-on-year to 6,767 billion. Net profit reached 752.9 million roubles that on 23% more than in the same period last year. Export sales grew by 36% year-on-year, exceeding 1 billion rubles, told in the company. Secondary sales […]

Russia confirmed on 5 065 new cases COVID-19

In recent days in Russia identified 5 065 new cases of coronavirus in 83 regions. Died 114 people, fully recovered 6 568 patients. In Moscow confirmed 688 new cases of coronavirus. The average rate of increase of new cases for the first two weeks of August is 0.28%. This figure compares with the first two […]